Investment analysts at HC Wainwright initiated coverage on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a note issued to investors on Tuesday, StockRatingsNetwork reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 84.21% from the company’s current price. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.95 moved to $7.99 on last trade day and at the end of the day closed at $7.60. Company price to sales ratio in past twelve months was calculated as 30.95 and price to cash ratio as 5.95.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA showed a negative weekly performance of -3.92%.
Merck & Co. (NYSE:MRK)‘s stock had its “neutral” rating reiterated byZacks in a report issued on Thursday, AnalystRatings.Net reports. They currently have a $59.00 price target on the stock. Zacks‘s price target points to a potential upside of 5.38% from the stock’s previous close. Merck & Co., Inc. (NYSE:MRK) shares fell -1.61% in last trading session and ended the day on $53.78. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 26.87%.
The Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. The net loss attributable to common stockholders for the quarter and year ended December 31, 2013, was $15.5 million, or $0.07 per share, and $66.0 million, or $0.36 per share, as compared with a net loss attributable to common stockholders of $659,000, or $0.00 per share, and $19.7 million, or $0.14 per share, for the quarter and year ended December 31, 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares moved down -4.88% in last trading session and was closed at $3.51, while trading in range of $3.43-$3.80.Inovio Pharmaceuticals Inc (NYSEMKT:INO) year to date performance is 21.03%.
Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating restated by Jefferies Group in a research note issued on Wednesday, AR Network reports. They currently have a $45.00 price target on the stock. Jefferies Group’s target price suggests a potential upside of 15.77% from the stock’s previous close.Abbott Laboratories (NYSE:ABT) weekly performance is -2.73%. On last trading day company shares ended up $38.43. Abbott Laboratories (NYSE:ABT) distance from 50-day simple moving average is -0.27%. Analysts mean target price for the company is $41.75.
Leave a Reply